BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Matthew S. Davids, Christoph Kornauth et al.|Blood|2021Cited by 37
Peripheral T- and natural killer-cell lymphomas: ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-upFrancesco d’Amore, Mats Jerkeman, François Lemonnier et al.|Annals of Oncology|2025Cited by 12
13 | PROGNOSTIC VALUE OF THE COMBINATION OF RADIOMICS PARAMETERS MEASURED ON BASELINE FDG PET/CT IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMAPierre Decazes, Vincent Camus, Cédric Rossi et al.|Hematological Oncology|2025Cited by 0